TEL/AML1-positive childhood acute lymphoblastic leukemias (ALLs) generally have low-risk features, but still about 20% of patients relapse. Our initial molecular genetic analyses in 2 off-treatment relapses suggested that the initial and relapse clones represent different subclones that evolved from a common TEL/AML1-positive, treatment-resistant precursor. In order to further elaborate on this hypothesis, we studied 2 patients with late systemic relapses of their TEL/AML1-positive ALL (41 months and 49 months after initial diagnosis, respectively) who had distinct clonal antigen receptor gene rearrangements at diagnosis and relapse. These clone-specific markers enabled us to determine the responsiveness of the individual clones to treatment. The matching genomic TEL/AML1 breakpoints of the initial and the relapse clones in these patients confirmed their origin from a common progenitor cell. This proof was especially important in one of these 2 leukemias without a common antigen receptor gene rearrangement. Our retrospective analysis revealed that in both cases the relapse clone was already present at diagnosis. Despite their small sizes (5 × 10−3 and 1 × 10−4, respectively), we were able to detect their much slower responses to therapy compared with the dominant leukemic clone. Moreover, in all instances, these initially slow-responding clones, after they had developed into the relapse leukemia, were rapidly eradicated by the relapse treatment, underlining their different biology at the 2 time points of leukemia manifestation. We thus hypothesize that the minor clone was not fully malignant at initial diagnosis but acquired further mutations that may be necessary for the manifestation of relapse.

Childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) is a heterogeneous disease with a variety of distinct genetic abnormalities. Approximately 25% of cases harbor a t(12;21) with the molecular equivalent of a TEL/AML1 gene fusion.1-3 Clinically, patients with this type of leukemia have low-risk features. Nevertheless, well-treatable relapses occur in about 20% of cases, typically after a long first remission period.4-10 However, the relapse incidence varies and depends on the respective treatment protocol.3-10 

The clone-specific TEL/AML1 gene fusion is readily detected in neonatal blood spots in most children with TEL/AML1-positive leukemia, proving that it occurred already in utero.11 The long latency between this first hit and the clinical manifestation suggests that further events are required to trigger the stepwise progression of the clone.12,13 One obvious candidate for such a contributing factor is the concurring deletion of the second TEL allele as seen in approximately 75% of TEL/AML1-positive cases.14 15 

Relapses are assumed to represent the re-emergence of the initial leukemic clone. This notion is derived from the finding that in the majority of cases the initial and the relapse clone share clonotypic antigen receptor gene rearrangements.16-19 Antigen receptor genes of normal lymphoid cells are rearranged during early development. Each cell and its progeny have their individual immunoglobulin/T-cell receptor (Ig/TCR) rearrangements, and therefore, they can be used for the characterization of a specific lymphoid cell population, particularly for clonality studies. Thereby, it was seen that oligoclonality is common in acute lymphoblastic leukemias.20-22 

We have recently shown in 2 patients with TEL/AML1-positive ALL that off-treatment relapses were not derived from the dominant clone at diagnosis but from a sibling clone as characterized by antigen receptor gene rearrangements and 12p status. Thus, it was speculated that both presentations of the leukemia were derived from a TEL/AML1-positive pre/leukemic clone.23 We now demonstrate that the relapse and the initial clone are derived from an identical TEL/AML1 preleukemic clone. Further, the pre/leukemic relapse clone is already present at initial diagnosis, but has a slower response to therapy compared with the dominant clone. In contrast, this clone responds rapidly to chemotherapy when it becomes the relapse leukemia.

Patients

We selected 2 children in whom the late systemic relapse clone from a TEL/AML1-positive leukemia differed with regard to the immune receptor rearrangements. Leukemic cells or DNA from both leukemic manifestations, as well as from follow-up bone marrow cells, were required for inclusion into this study. Written informed consent was obtained from the patients or their guardians. The study was approved by the ethical committee of the Children's Cancer Research Institute and the St Anna Kinderspital.

Fluorescence in situ hybridization analysis

Dual-color fluorescence in situ hybridization (FISH) was performed according to standard methods on methanol/acetic acid-fixed samples of cells that were cultured for 24 hours. For the analysis of the TEL/AML1 gene fusion, 2 cosmids (50F4 and cos664) were used that are specific for the TEL and AML1 locuses, respectively. The TEL probe covers 35 kb of intron 1 and exon 2. We screened at least 100 nuclei per sample and analyzed DNA preparation from fresh cells. Mononuclear cells (MNCs) were isolated from bone marrow (BM) samples using Ficoll-Paque (1.077 g/mL; Pharmacia, Uppsala, Sweden) density gradient centrifugation. DNA was extracted by QIAamp Blood Kit (QIAGEN, Chatsworth, CA). Integrity of the DNA was confirmed by amplification of albumin as previously described.24 By amplification of this control gene the amount of DNA was measured in all samples, compared with a standard, and corrected accordingly.

Determination of leukemia clone-specific antigen receptor gene rearrangements

Polymerase chain reaction (PCR) amplification of incomplete and complete IgH rearrangements was performed using family-specific DH and VH primers, respectively, and one JH consensus primer, as previously described.25 For the detection of the IgK–kappa deleting element (KDE) rearrangements we used 4 Vk primers and an intron recombination signal sequence (RSS) primer in combination with a KDE primer. Sequence of the primers and PCR conditions were used as described previously.26 PCR for the detection of incomplete TCRD (Dδ2-Dδ3, Vδ2-Dδ3) rearrangements and of TCRG rearrangements (VγI-Jγ.1/2.1, VγII-Jγ1.1/2.1, VγI-Jγ1.3/2.3, VγII-Jγ1.3/2.3) was performed as previously described.26 All primers were purchased from a commercial supplier (Invitrogen, Carlsbad, CA).

An aliquot of 500 ng DNA was used for each amplification reaction in a 50 μL volume of 1× buffer (Applied Biosystems, Foster City, CA) containing 200 nM of each deoxynucleotide triphosphate (dNTP), 30 pmol of each primer, and 0.5 U AmpliTaq Gold (Applied Biosystems). Amplifications were performed on a Thermocycler (PTC-200; Techne, Cambridge, United Kingdom). PCR products were then size-fractionated on 4% to 12% nondenaturing polyacrylamide gels (Invitrogen) and analyzed for heteroduplex formation in order to see if more than one clonal product of identical size was present and to separate clonal bands from polyclonal background.26 After elution in water, PCR products were directly sequenced (VBC Genomics, Vienna, Austria). All sequences were confirmed in different independent PCR reactions.

The involved gene segments were identified by the Imunogenetics Database (IMGT; http://www.ebi.ac.uk/imgt/), and all Ig rearrangements by comparison with sequences of all known human Ig genes obtained from the IGBlast (http://www.ncbi.nlm.nih.goc/blast/) or VBASE directory (http://www.mrc-cpe.cam.ac.uk/imt-doc/).

Determination of genomic TEL/AML1 breakpoints

Breakpoint-spanning DNA fragments were amplified by nested long-range PCR. Primer sequences were deduced from gene bank sequence data covering the breakpoint cluster regions of both genes involved, TEL (U61375) and AML1 (AP001721), respectively, and designed with the help of OMIGA software (Oxford Molecular, Oxford, England). PCR was performed on an Eppendorf Mastercycler Gradient (Eppendorf, Hamburg, Germany). We used 2 nested primer sets located within exon 5 and intron 5 of TEL, respectively, together with 16 primer sets located within intron 1 of AML1 in all combinations possible. PCR was performed with a conventional kit (Gene Amp XL, Perkin Elmer, Foster City, CA) following the manufacturer's recommendations using 50 ng template DNA. Cycling conditions consisted of an initial denaturation step at 92°C for 2 minutes, followed by 30 cycles (92°C for 10 seconds, 68°C for 10 minutes and 30 seconds). The first-round PCR product (1 μL) was used as template for the nested reaction. Amplified products were excised from agarose gels, eluted, and directly sequenced. By using this approach, a breakpoint-spanning DNA sequence was obtained from patient 2 only. In patient 1, we assumed that the negative result was due to the breakpoint located within intron 2 of AML1, as is the case in about 20% of t(12;21) translocations. Intron 2 of AML1, however, is very rich in G/C residues. For this reason, a different set of 8 nested PCR primers was used to keep the size of possible PCR products lower. We combined 4 nested PCR primers binding within intron 2 of AML1 with 4 TEL primers. The PCR reaction mix was also modified to destabilize G/C bonds. PCR was performed in a total volume of 50 μL containing 100 ng template DNA, 1× buffer (Invitrogen), 12.5 μL enhancer-solution, 50 mM magnesium chloride, 10 mM of each dNTP (Biozyme, Heidelberg, Germany), 20 μM of each primer, and 1 U Taq polymerase (Taq DNA Polymerase; Invitrogen). Initial denaturation for 2 minutes at 94°C was followed by 35 cycles (94°C for 10 seconds, 68°C for 3 minutes) and a final annealing/extension step for 7 minutes. PCR primers giving rise to a product in both approaches are listed in Table 1. Primers for amplification of the derivative 21 breakpoint in patient 1 were selected on basis of the derivative 12 sequence.

Table 1.

Primers used for amplification, sequencing, and quantification of TEL/AML1 breakpoints

PrimerNucleotide sequenceGenePosition*PCR/sequencing
P1 GCCCTTACATTGGAGAAATGGTCTGGTTCA CG TEL 10944-10975 1st 
P2 AGTGGAGTGCCTTCCGCTAAGCAAG TEL 11106-11133 2nd 
P3 GGATAAAAGACAGGAAGCCGCCCCAG AML1 159009-158984 1st 
P4 CGTTTCCGAGGTTCCAATATAGAGTCGCAG AML1 158954-158925 2nd 
P5 CTCTCCGGTGATCCACAATCAACAGTGAGATG AML1 150763-150794 1st 
P6 CAGTGAGATGACAAAGGAGTCAAGCAGATGGAG AML1 150785-150817 2nd 
P7 CTTAAACCTGGGCAGAACCCATGTGAAAGACGG TEL 14589-14557 1st 
P8 GACGGGAGGCAAGTTCTAACTGAATCAATGGG TEL 14561-14530 2nd 
P9 CTCAGCCCATCCCCTGGCAATACAGAATG TEL 12393-12419 1st 
P10 AGGAGGCCACTTGTCCTTTTCCAAAACACAATG TEL 12519-12551 2nd 
P11 GGGAGCTGCGCTGTCAAATTGAGTCAGG AML1 144301-144274 1st 
P12 ACAGTGAACTCACTCTAGGAGACCCGCACG AML1 144227-144198 2nd 
P13 TCTGCCAGTGTCTTCTGT TEL 12689-12706 Seq 
P14 GGCCTGGCACATTTGAAAGG TEL 13322-13302 Seq 
P15 CTAGCCCACAGCCAAAAACC TEL 14046-14065 Seq 
P16 GAATAGCAACAGCACCTGCCT TEL NA Tq 
P17 GCTTAGTAAACATTTTACTCTCAGTGGG AML1 NA Tq 
P18 ATAAGGCGGCGTAAGGGTCAGATGTAACC TEL NA Pro 
P19 TATCTGTATCTCTTTTTGAAACCATGC TEL NA Tq 
P20 GGGACCAATGATTCAGGATATGTAAC AML1 NA Tq 
P21 CCACAGTTCCCACAGTCAGAGTCACCAAG TEL NA Pro 
P22 GGAGATCCAGGTCTTATTGGTCC APM-1 NA Tq 
P23 GCTGAGCGGTATACATAGGC APM-1 NA Tq 
P24 CATCGGTGAAACCGGAGTACCCGG APM-1 NA Pro 
PrimerNucleotide sequenceGenePosition*PCR/sequencing
P1 GCCCTTACATTGGAGAAATGGTCTGGTTCA CG TEL 10944-10975 1st 
P2 AGTGGAGTGCCTTCCGCTAAGCAAG TEL 11106-11133 2nd 
P3 GGATAAAAGACAGGAAGCCGCCCCAG AML1 159009-158984 1st 
P4 CGTTTCCGAGGTTCCAATATAGAGTCGCAG AML1 158954-158925 2nd 
P5 CTCTCCGGTGATCCACAATCAACAGTGAGATG AML1 150763-150794 1st 
P6 CAGTGAGATGACAAAGGAGTCAAGCAGATGGAG AML1 150785-150817 2nd 
P7 CTTAAACCTGGGCAGAACCCATGTGAAAGACGG TEL 14589-14557 1st 
P8 GACGGGAGGCAAGTTCTAACTGAATCAATGGG TEL 14561-14530 2nd 
P9 CTCAGCCCATCCCCTGGCAATACAGAATG TEL 12393-12419 1st 
P10 AGGAGGCCACTTGTCCTTTTCCAAAACACAATG TEL 12519-12551 2nd 
P11 GGGAGCTGCGCTGTCAAATTGAGTCAGG AML1 144301-144274 1st 
P12 ACAGTGAACTCACTCTAGGAGACCCGCACG AML1 144227-144198 2nd 
P13 TCTGCCAGTGTCTTCTGT TEL 12689-12706 Seq 
P14 GGCCTGGCACATTTGAAAGG TEL 13322-13302 Seq 
P15 CTAGCCCACAGCCAAAAACC TEL 14046-14065 Seq 
P16 GAATAGCAACAGCACCTGCCT TEL NA Tq 
P17 GCTTAGTAAACATTTTACTCTCAGTGGG AML1 NA Tq 
P18 ATAAGGCGGCGTAAGGGTCAGATGTAACC TEL NA Pro 
P19 TATCTGTATCTCTTTTTGAAACCATGC TEL NA Tq 
P20 GGGACCAATGATTCAGGATATGTAAC AML1 NA Tq 
P21 CCACAGTTCCCACAGTCAGAGTCACCAAG TEL NA Pro 
P22 GGAGATCCAGGTCTTATTGGTCC APM-1 NA Tq 
P23 GCTGAGCGGTATACATAGGC APM-1 NA Tq 
P24 CATCGGTGAAACCGGAGTACCCGG APM-1 NA Pro 
*

In all TEL primers, numbering starts with the first nucleotide of exon 5; in the case of AML1, numbers start with the first nucleotide of exon 1.

Indicates the use of the primer either for PCR round 1 and round 2, sequencing (Seq), as TaqMan primers (Tq), or as TaqMan probes (Pro).

NA indicates not applicable.

Clone-specific PCR

Clone-specific oligonucleotide primers were designed homologous to the junctional regions of the Ig/TCR rearrangements and used for quantitative PCR, as previously described.24 Optimal thermocycling conditions were established for each patient-specific primer pair to detect the clone-specific sequence. The specificity and sensitivity of the primer combinations was determined for each clonal marker on DNA from either initial or relapse leukemia according to their presence in the screening PCR. Leukemic DNA was diluted (10−1 to 10−7) in DNA from peripheral blood MNCs from healthy donors.

DNA for Ig/TCR and TEL/AML gene fusions (500 ng and 100 ng, respectively) was used as a template in a 50-μL reaction volume. Negative controls were included in each experiment: one sample containing the reaction mix without DNA, and another sample containing DNA from peripheral blood MNCs from healthy donors as a polyclonal control. DNA obtained at diagnosis from each patient was used as a positive control. Samples and controls were always analyzed in triplicate. Precautions to avoid contamination were followed as previously described.27 

The 2 children had a late systemic relapse of their TEL/AML1-positive ALL. The clinical data as well as the duration of first remission are listed in Table 2. The children are still in second complete continuous remission (CCR). The children received chemotherapy for non–high-risk leukemias of the Berlin-Frankfurt-Münster (BFM) ALL 90 protocol in Austria.28 Remission induction chemotherapy consisted of one week prednisone (60 mg/m2 per day) plus one intrathecal methotrexate application on day 1, followed by weekly administrations of intravenous vincristine (1.5 mg/m2) and daunorubicine per infusion (30 mg/m2). Asparaginase infusions (10.000 IE/m2) were given twice a week for 4 weeks. On day 33 the morphologic remission status was evaluated in the bone marrow. Relapses were treated according to the BFM Rez ALL 95 study.29 The first treatment block consisted of dexamethasone 20 mg/m2 on days 1 to 5, triple intrathecal administration on day 1, vincristine 1.5 mg/m2 on days 1 and 6, methotrexate 1000 mg/m2per infusion (36 hours) on day 1 and E coli–asparaginase 10.000 IE/m2 on day 4 (infused over 24 hours). Both patients achieved a morphologic remission after the initial and relapse induction chemotherapy, respectively.

Table 2.

Clinical data of patients

Patient no.Sex/age in years at initial diagnosisBlasts (%) in bone marrowRemission, in months 1st CCR/2nd CCR
At initial diagnosisAt relapse
M/4.3 87 94 48/35 
F/1.9 96 94 40/78 
Patient no.Sex/age in years at initial diagnosisBlasts (%) in bone marrowRemission, in months 1st CCR/2nd CCR
At initial diagnosisAt relapse
M/4.3 87 94 48/35 
F/1.9 96 94 40/78 

In the first patient, we found a total of 6 rearrangements, 4 at diagnosis and 2 different, completely unrelated ones at relapse. In the second patient, we identified 5 distinct rearrangements at diagnosis and 6 at relapse, one of which was found in both instances. Based on our results that in both leukemias a maximum of 2 different rearrangements per antigen receptor gene were detected, we concluded that the initial diseases and relapses were monoclonal. Thus, with regard to the antigen gene receptor gene rearrangements, the diagnostic and relapse samples of the first patient appeared as having arisen from 2 completely unrelated clones. This is in contrast to the second patient, in whom a clonal relationship between diagnostic and relapse leukemia was evident.

TEL/AML1 FISH reveals clonal diversification

The first patient had a TEL/AML1-positive as well as TEL/AML1-negative cell population, but both with very similar secondary changes. At diagnosis, a deletion of one TEL allele was seen in 9 of 13 TEL/AML1-negative metaphases. A TEL/AML1 fusion was present in 81% of the 80 analyzable interphase cells. The following percentages always refer to the whole number of analyzed interphase cells. The 19% TEL/AML1-negative cells comprised some with a TEL deletion together with an additional AML1 signal (3.8%, indicative of the presence of an additional chromosome 21), whereas 7.6% had none of these changes. Another 7.6% had 2 additional AML1 signals, but no TEL deletion. The TEL/AML1-positive cell population consisted of 31% with and 50% without a TEL deletion. The former comprised 23% with 2 and 7.6% with 3 and the latter 3.8% with one, 31% with 2, and 15.3% with 3 extra AML1 signals. In the relapse sample we were able to screen 130 cell nuclei, of which 48% were TEL/AML1-negative and 15% TEL/AML1-negative, but with a TEL deletion. The 37% TEL/AML1-positive cells included 7% with only a TEL deletion, 10% with 2 extra AML1 signals, and 20% without a TEL deletion, but with one extra AML1 signal.

In summary, these FISH data suggest that in the first patient all TEL/AML1-negative and -positive clones were also present in the relapse sample, albeit with a different distribution. This clonal heterogeneity most likely indicates that the TEL/AML1 gene fusion and the subsequent clonal evolution have occurred in a transformed clone before the immune receptor rearrangements.

In the second patient, a colocalization of the TEL and AML1 signals was found in 62% of interphase cells from the diagnostic sample. Moreover, in line with the presence of an additional derivative chromosome 21, der(21), 7% of nuclei showed a second colocalization, whereas the absence of a noncolocalized TEL signal indicated that the residual TEL allele was deleted in this cell population. In the relapse sample, on the other hand, 74% of nuclei contained a TEL/AML1 gene fusion and 48% of them had 2 colocalizations, whereas the signal for the second TEL allele was always present. In this patient the relapse clone without TEL deletion could not have evolved from the diagnostic clone with a deleted TEL.

Initial leukemia and relapse are derived from a patient-specific TEL/AML1 leukemic progenitor cell

To test our hypothesis that the clones from initial disease and relapse are derived from a common TEL/AML1-positive progenitor cell, we cloned the patient-specific TEL/AML1 and the reciprocal AML1/TEL fusion sites on the DNA level. In the first patient, the primer combinations P1/P3 and P2/P4 revealed a breakpoint-spanning PCR product of the AML1/TEL fusion on the derivative chromosome 12, der(12), in intron 5 of the TEL and in intron 2 of the AML1 gene. Sequencing was performed with primer P13. Sequence data were deposited in public databases (accession number AJ494735). TaqMan real-time PCR was performed with primers P16/P17 and the probe P18. In this patient, also a TEL/AML1 breakpoint-spanning DNA fragment on the der(21) was amplified with primers P5/P7 and P6/P8 and sequenced using primer P14. In the second patient, the der(12) genomic breakpoint was detected in the intron 5 of TEL and in intron 1 of AML1 with the primer combinations P9/P11 and P10/P12. Sequencing was performed with primer P15 (database accession number AJ494736). Real-time PCR was performed with P19/P20 and the probe P21. Primers P22/P23 and probe P24 were used to quantifiy the single copy gene APM-1 as a basis for calculating the number of TEL/AML1-positive cells in each sample. The breakpoint sequences, identified in the diagnostic and relapse samples, were clonotypic for each patient demonstrating unambiguously the common clonal origin of the leukemia.

Relapse originates from a small subclone present at diagnosis

The individual configurations of the immune receptor gene rearrangements enabled us to retrospectively confirm that the relapse clones were actually already present at diagnosis in both patients (Table 3). In the first patient, the relapse clone with its specific TCRGc and TCRGd gene rearrangements constituted only approximately 1 in 104cells at the time of diagnosis. The relapse clone of the second patient, which was defined by unique IgHd, TCRDb, and TCRGb gene rearrangements, comprised 0.5% of the initial leukemic cell load. However, despite a high sensitivity (10−4) of the allele-specific PCR, we were unable to detect 2 of the relapse-specific rearrangements (IgHc and TCRGc) in this patient (Table 3). These rearrangements were also not found in samples that were obtained during the complete treatment phase (data not shown). We therefore presume that the relapse clone had evolved from a cell with ongoing recombinatorial potential that was related to the smaller subclone at diagnosis. We also used clone-specific PCR to find out whether the initial clone might have persisted (Table 3). However, in neither case were the respective clonotypic rearrangements detectable.

Table 3.

Antigen receptor gene rearrangements of the leukemias at initial diagnosis and relapse as determined by screening PCR and clonotoypic ASO PCR

Rearrangement3-150Initial diagnosisRelapse
Patient 1   
 IGH VH3-33/DH2-2/J6 Negative 
 TCRD Vδ2-Dδ3 Negative 
 TCRGa Vγ9-Jγ1.3/2.3 Negative3-151 
 TCRGb Vγ3-Jγ1.3/2.3 Negative3-151 
 TCRGc 10−4 VγI-Jγ1.3/2.3a3-152 
 TCRGd 10−4 VγI-Jγ1.3/2.3b3-152 
Patient 2   
 IGHa VH1-2/DH2-2/J6 Negative 
 IGHb VH3-66/J3 Negative  
 IGHc Negative VH3-13/J5 
 IGHd 5 × 10−3 VH3-33/J4 
 IGK-KDE RSS-KDE RSS-KDE 
 TCRDa Vδ2-Dδ3 Negative3-151 
 TCRDb 5 × 10−3 Vδ2-Dδ3 
 TCRGa Vγ3-Jγ1.3/2.3 Negative  
 TCRGb 5 × 10−3 Vγ2-Jγ1.3/2.3 
 TCRGc Negative Vγ5-Jγ1.3/2.3 
Rearrangement3-150Initial diagnosisRelapse
Patient 1   
 IGH VH3-33/DH2-2/J6 Negative 
 TCRD Vδ2-Dδ3 Negative 
 TCRGa Vγ9-Jγ1.3/2.3 Negative3-151 
 TCRGb Vγ3-Jγ1.3/2.3 Negative3-151 
 TCRGc 10−4 VγI-Jγ1.3/2.3a3-152 
 TCRGd 10−4 VγI-Jγ1.3/2.3b3-152 
Patient 2   
 IGHa VH1-2/DH2-2/J6 Negative 
 IGHb VH3-66/J3 Negative  
 IGHc Negative VH3-13/J5 
 IGHd 5 × 10−3 VH3-33/J4 
 IGK-KDE RSS-KDE RSS-KDE 
 TCRDa Vδ2-Dδ3 Negative3-151 
 TCRDb 5 × 10−3 Vδ2-Dδ3 
 TCRGa Vγ3-Jγ1.3/2.3 Negative  
 TCRGb 5 × 10−3 Vγ2-Jγ1.3/2.3 
 TCRGc Negative Vγ5-Jγ1.3/2.3 

Negative indicates negative by clone-specific quantitative PCR (at a sensitivity of 10−4 or more).

F3-150

The letters a, b, c, d indicate the different rearrangements of one respective antigen receptor gene.

F3-151

Negative by screening PCR (but not tested by clone-specific quantitative PCR).

F3-152

Sequences were too short to identify the member of the Vgl family.

Subclones show a different response to initial and relapse chemotherapy

In both children the response of the different subclones to treatment was evaluated by quantitative PCR of the unique rearrangements from the initial and relapse leukemias, respectively (Figure 1). In patient 1, both leukemic subclones had an initial slow response after 2 weeks of treatment, although it was even slower in the minor subclone. One cell of the dominant clone was still detectable among 100 normal cells at day 15 as analyzed by the IgH and TCRD rearrangements, whereas the relapse clone, detected through its 2 TCRG rearrangements, persisted at similar low levels (10−4) as before treatment. These clones remained undetectable at all time points including 2 months after the end of chemotherapy. No further samples were obtained until relapse. The leukemia at relapse responded very promptly to chemotherapy as shown in Figure 1.

Fig. 1.

Response of individual subclones from TEL/AML1-positive leukemias to treatment.

The presence of the dominant leukemic clones and the relapse clones was analyzed by quantitative clone-specific PCR in diagnostic, follow-up (indicated by the months after diagnosis at which samples were obtained), and relapse bone marrow MNCs as described (see “Patients, materials, and methods”). ● indicates the dominant leukemic clone at diagnosis as detected by immune receptor rearrangements (patient 1 [pt 1]: IgH, TCRD; pt 2: IgHb, TCRDa, TCRGa); ▴ shows the relapse clone detected by immune receptor rearrangements (pt 1: TCRGa and b; pt 2: IgHd, TCRDb, TCRGb); filled symbols indicate a quantifiable amount of the clone (more than 5 × 10−5); open symbols indicate lack of detection; * indicates the amount of the TEL/AML1 genomic fusion gene as determined by patient-specific breakpoint PCRs.

Fig. 1.

Response of individual subclones from TEL/AML1-positive leukemias to treatment.

The presence of the dominant leukemic clones and the relapse clones was analyzed by quantitative clone-specific PCR in diagnostic, follow-up (indicated by the months after diagnosis at which samples were obtained), and relapse bone marrow MNCs as described (see “Patients, materials, and methods”). ● indicates the dominant leukemic clone at diagnosis as detected by immune receptor rearrangements (patient 1 [pt 1]: IgH, TCRD; pt 2: IgHb, TCRDa, TCRGa); ▴ shows the relapse clone detected by immune receptor rearrangements (pt 1: TCRGa and b; pt 2: IgHd, TCRDb, TCRGb); filled symbols indicate a quantifiable amount of the clone (more than 5 × 10−5); open symbols indicate lack of detection; * indicates the amount of the TEL/AML1 genomic fusion gene as determined by patient-specific breakpoint PCRs.

Close modal

In patient 2, the dominant clone at initial diagnosis was not detected (< 10−4) anymore at day 15 through its clonotypic rearrangements IgHb, TCRDa, and TCRGa, whereas the relapse clone characterized by the IgHd, TCRDb, and TCRGb rearrangements had a slower response (10−3 at day 15, 10−4 at week 5) and persisted at low levels for 9 months. This slow response of the relapse clone to initial therapy contrasts with its rapid reduction by the relapse therapy, which resembles the fast response of the dominant clone to initial therapy. The common IgK-KDE rearrangement was traceable during follow-up at the same levels as the relapse rearrangements. None of the rearrangements was detectable in bone marrow samples obtained at 12 months and 18 months after initial diagnosis. At 2 months after the end of treatment (26 months after initial diagnosis) only one of the relapse-specific IgH rearrangements (IgHd) was detectable at a low level, whereas the clinical manifestation of the relapse occurred 15 months later.

To test whether quantification of the TEL/AML1 breakpoints would confirm the results obtained by immune receptor gene analysis, or detect a higher copy number of the TEL/AML1 fusion gene, we applied patient-specific TEL/AML1 real-time TaqMan PCRs using primers 16/17 and 19/20 and probes 18 and 21, for patient 1 and 2, respectively (Table1). We detected similar amounts of PCR products in all diagnostic and follow-up samples (indicated by an asterisk in Figure 1), thereby confirming the slower response and the persistence of the relapse clone, as well as the lack of amplification during later phases of the chemotherapy.

In 2 children with late systemic relapses of their TEL/AML1-positive leukemias we show that the initial and the relapse leukemias arise independently from a common TEL/AML1 precursor cell. At initial diagnosis, the dominant clone was sensitive to therapy, whereas the subclone, which later developed into the relapse leukemia, responded poorly. At the time of relapse, however, this clone was sensitive to treatment.

The differentiation stage of a transformed lymphoid cell can be characterized by its immune receptor rearrangements. These rearrangements occur independently from the oncogenic process. Thus, they can be used as markers for the timing of molecular events during leukemogenesis as well as for determining the time point of an early event during ontogeny (fetal versus postnatal development).30-34 We propose an order of molecular events during leukemogenesis, which is based on a current model by M. Greaves.35,36 Accordingly, at least 2 “hits” are required for the manifestation of leukemia. The TEL/AML1 translocation might be such a “first hit” in a precursor cell, either before the onset of somatic recombination, or, at a later stage, when immune receptor genes rearrange. Thus, continuing rearrangement processes lead to a variety of immune receptor rearrangements in individual cells of the TEL/AML1-positive preleukemic clone, resulting in a heterogeneous population. A second crucial molecular hit, probably a deletion of the nonrearranged TEL allele, drives one of these cells to overt leukemia. The following chemotherapy eradicates that leukemia, while the preleukemic clone may survive. If one of these preleukemic cells acquires a second mutation another leukemia develops, which harbors an identical TEL/AML1 gene fusion, but may carry a different TEL deletion and also different Ig/TCR gene rearrangements. In both patients the identical TEL/AML1 gene fusion was found at initial manifestation of the leukemia and at relapse. This gene fusion presumably transformed a cell with its immune receptor genes in germ line configuration or with an IgK rearrangement in patients 1 and 2, respectively, which may, on some occasions, precede IgH rearrangements.37 The difference in the TEL deletion status between initial presentation and relapse in patient 2 concords with the proposed model, whereas the clonal heterogeneity in the first patient makes an interpretation and valid conclusion extremely difficult. At initial presentation of the leukemia, the relapse clones ranged from 10−4 to 5 × 10−3 in the bone marrow of the 2 patients. Although this seems comparatively large, it is nevertheless only in the same order of magnitude as that of the pre/leukemic clones, which are retrospectively detected in peripheral blood obtained after birth from children with ALL.11,38 These data further suggest that a preleukemic clone maintains its size during its entire life span until it either undergoes apoptosis or is eradicated by chemotherapy. This assumption is further supported by the finding that the size of a pre/leukemic or covert leukemic clone carrying the TEL/AML1 gene fusion in neonates who do not develop leukemia is similar to the preleukemic subclone at diagnosis from the 2 patients in this report.36 

Patient 2 from our study had a long persistence of the minor pre/leukemic subclone. Likewise, the persistence of a preleukemic clone carrying the leukemia-specific fusion gene during morphologic remission has been reported in patients with acute myeloid leukemia with the t(8;21) chromosomal translocation. Thereby, the AML/ETO fusion gene resides in a preleukemic multipotent stem cell, which is resistant to treatment and develops to overt leukemia due to secondary genetic events.39-42 

A rapid and sustained disappearance of the dominant leukemia clones and a slow response of the smaller clones to first chemotherapy were observed in both children. According to current concepts, the slow response of the minor clones results from a primary drug resistance. In-line, slow-responding subclones were described previously in children with TEL/AML1-negative ALL.43 These patients experienced an early disease recurrence, whereas the 2 patients from this report had long first remission durations of 48 months and 40 months, respectively. Typically, TEL/AML1-positive leukemias have late relapses as exemplified by the cases from this report. These relapses respond very well to relapse chemotherapy with persistent or long-lasting second remissions.8 Such biologic differences between TEL/AML1-positive and -negative leukemias allow an alternative interpretation, that is, that these minor—presumably preleukemic—subclones have a poor response to therapy because they have a slower cell cycle than the fully leukemic clones.23-44 These initially slow-proliferating subclones may change their proliferation kinetics due to the acquisition of molecular events that lead to the manifestation of the relapse, and thus become well treatable. An intrinsic effect of the relapse protocol, however, cannot be excluded.

The observation from the 2 cases reported here should, however, not suggest the exclusive use of breakpoint-specific sequences for MRD analysis—even though Ig/TCR rearrangements may not be conserved at relapse—because the presence of a TEL/AML1 fusion gene does not always indicate a malignant disease.36-45 Currently, we cannot yet distinguish preleukemic clones from leukemias.

In conclusion, we have shown that a minor subclone of TEL/AML1-positive ALL responds slowly to chemotherapy, whereas the major clone has a rapid response. This biologic behavior of the smaller subclone during first chemotherapy can be interpreted as a feature of the preleukemic stage, which contrasts its very rapid response when it has evolved to the relapse leukemia.

This study was performed using the network of the Biology Group within the I-BFM Group. We would like to thank Uli Monschein and Marion Zavadil for help in preparing the manuscript.

Prepublished online as Blood First Edition Paper, December 27, 2002; DOI 10.1182/blood-2002-10-3252.

Supported in part by a grant from the FWF 13757-MED (E.R.P.-G.) and by the “Österreichische Kinderkrebshilfe.”

M.K. and M.M. contributed equally to the content of this paper.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Loh
ML
Rubnitz
JE
TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches.
Curr Opin Hematol.
9
2002
345
352
2
Shurtleff
SA
Buijs
A
Behm
FG
et al
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.
Leukemia.
9
1995
1985
1989
3
Rubnitz
JE
Shuster
JJ
Land
VJ
et al
Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study.
Blood.
89
1997
1143
1146
4
Maloney
K
McGavran
L
Murphy
J
et al
TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification.
Leukemia.
13
1999
1708
1712
5
McLean
TW
Ringold
S
Neuberg
D
et al
TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia.
Blood.
88
1996
4252
4258
6
Loh
ML
Silverman
LB
Young
ML
et al
Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia.
Blood.
92
1998
4792
4797
7
Harbott
J
Viehmann
S
Borkhardt
A
Henze
G
Lampert
F
Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse.
Blood.
90
1997
4933
4937
8
Seeger
K
Adams
HP
Buchwald
D
et al
TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group.
Blood.
91
1998
1716
1722
9
Rubnitz
JE
Behm
FG
Wichlan
D
et al
Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup.
Leukemia.
13
1999
19
21
10
Seeger
K
Buchwald
D
Taube
T
et al
TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Berlin-Frankfurt-Munster Study Group.
Leukemia.
13
1999
1469
1470
11
Wiemels
JL
Cazzaniga
G
Daniotti
M
et al
Prenatal origin of acute lymphoblastic leukaemia in children.
Lancet.
354
1999
1499
1503
12
Wiemels
JL
Ford
AM
van Wering
ER
Postma
A
Greaves
M
Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero.
Blood.
94
1999
1057
1062
13
Ford
AM
Bennett
CA
Price
CM
Bruin
MC
van Wering
ER
Greaves
M
Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia.
Proc Natl Acad Sci U S A.
95
1998
4584
4588
14
Romana
SP
Le Coniat
M
Poirel
H
Marynen
P
Bernard
O
Berger
R
Deletion of the short arm of chromosome 12 is a secondary event in acute lymphoblastic leukemia with t(12;21).
Leukemia.
10
1996
167
170
15
Raynaud
S
Cave
H
Baens
M
et al
The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia.
Blood.
87
1996
2891
2899
16
Steward
CG
Goulden
NJ
Katz
F
et al
A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia.
Blood.
83
1994
1355
1362
17
Szczepanski
T
Willemse
MJ
Brinkhof
B
van Wering
ER
van der
BM
van Dongen
JJ
Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease.
Blood.
99
2002
2315
2323
18
Levasseur
M
Maung
ZT
Jackson
GH
Kernahan
J
Proctor
SJ
Middleton
PG
Relapse of acute lymphoblastic leukaemia 14 years after presentation: use of molecular techniques to confirm true re-emergence.
Br J Haematol.
87
1994
437
438
19
Vora
A
Frost
L
Goodeve
A
et al
Late relapsing childhood lymphoblastic leukemia.
Blood.
92
1998
2334
2337
20
Beishuizen
A
Hahlen
K
Hagemeijer
A
et al
Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin.
Leukemia.
5
1991
657
667
21
Deane
M
Pappas
H
Norton
JD
Immunoglobulin heavy chain gene fingerprinting reveals widespread oligoclonality in B-lineage acute lymphoblastic leukaemia.
Leukemia.
5
1991
832
838
22
Steenbergen
EJ
Verhagen
OJ
van Leeuwen
EF
dem Borne
AE
van der Schoot
CE
Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia.
Blood.
82
1993
581
589
23
Ford
AM
Fasching
K
Panzer-Grümayer
ER
Koenig
M
Haas
OA
Greaves
MF
Origins of “late” relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes.
Blood.
98
2001
558
564
24
Szczepanski T, van der Velden V, van Dongen JJ. Real-time quantitative (RQ)-PCR for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Hematologica. In press.
25
Szczepanski
T
Pongers-Willemse
MJ
Langerak
AW
et al
Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6–19 and DH7–27 gene usage can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage.
Blood.
93
1999
4079
4085
26
Pongers-Willemse
MJ
Seriu
T
Stolz
F
et al
Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Leukemia.
13
1999
110
118
27
Ghali
DW
Panzer
S
Fischer
S
et al
Heterogeneity of the T-cell receptor delta gene indicating subclone formation in acute precursor B-cell leukemias.
Blood.
85
1995
2795
2801
28
Schrappe
M
Reiter
A
Ludwig
WD
et al
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
Blood.
95
2000
3310
3322
29
Henze G. Chemotherapy for relapsed childhood acute lymphoblastic leukemia. Int J Pediatr Hematol Oncol. In press.
30
Wasserman
R
Galili
N
Ito
Y
Reichard
BA
Shane
S
Rovera
G
Predominance of fetal type DJH joining in young children with B precursor lymphoblastic leukemia as evidence for an in utero transforming event.
J Exp Med.
176
1992
1577
1581
31
Steenbergen
EJ
Verhagen
OJ
van Leeuwen
EF
et al
B precursor acute lymphoblastic leukemia third complementarity-determining regions predominantly represent an unbiased recombination repertoire: leukemic transformation frequently occurs in fetal life.
Eur J Immunol.
24
1994
900
908
32
Schneider
M
Panzer
S
Stolz
F
Fischer
S
Gadner
H
Panzer-Grümayer
ER
Crosslineage TCR delta rearrangements occur shortly after the DJ joinings of the IgH genes in childhood precursor B ALL and display age-specific characteristics.
Br J Haematol.
99
1997
115
121
33
Panzer-Grümayer
ER
Fasching
K
Panzer
S
et al
Nondisjunction of chromosomes leading to hyperdiploid childhood B-cell precursor acute lymphoblastic leukemia is an early event during leukemogenesis.
Blood.
100
2002
347
349
34
Fasching
K
Panzer
S
Haas
OA
et al
Presence of N regions in the clonotypic DJ rearrangements of the immunoglobulin heavy-chain genes indicates an exquisitely short latency in t(4;11)-positive infant acute lymphoblastic leukemia.
Blood.
98
2001
2272
2274
35
Greaves
M
Molecular genetics, natural history and the demise of childhood leukaemia.
Eur J Cancer.
35
1999
173
185
36
Mori
H
Colman
SM
Xiao
Z
et al
Chromosome translocations and covert leukemic clones are generated during normal fetal development.
Proc Natl Acad Sci U S A.
99
2002
8242
8247
37
Kubagawa
H
Cooper
MD
Carroll
AJ
Burrows
PD
Light chain gene expression before heavy chain gene rearrangement in pre-B cells transformed by Epstein-Barr virus.
Proc Natl Acad Sci U S A.
86
1989
2356
2360
38
Fasching
K
Panzer
S
Haas
OA
Marschalek
R
Gadner
H
Panzer-Grümayer
ER
Presence of clone-specific antigen receptor gene rearrangements at birth indicates an in utero origin of diverse types of early childhood acute lymphoblastic leukemia.
Blood.
95
2000
2722
2724
39
Wiemels
JL
Xiao
Z
Buffler
PA
et al
In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia.
Blood.
99
2002
3801
3805
40
Nucifora
G
Larson
RA
Rowley
JD
Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission.
Blood.
82
1993
712
715
41
Miyamoto
T
Nagafuji
K
Akashi
K
et al
Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
Blood.
87
1996
4789
4796
42
Miyamoto
T
Weissman
IL
Akashi
K
AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.
Proc Natl Acad Sci U S A.
97
2000
7521
7526
43
de Haas
V
Verhagen
OJ
dem Borne
AE
Kroes
W
van den
BH
van der Schoot
CE
Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy.
Leukemia.
15
2001
134
140
44
Rompaey
LV
Potter
M
Adams
C
Grosveld
G
Tel induces a G1 arrest and suppresses Ras-induced transformation.
Oncogene.
19
2000
5244
5250
45
Eguchi-Ishimae
M
Eguchi
M
Ishii
E
et al
Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals.
Blood.
97
2001
737
743

Author notes

E. Renate Panzer-Grümayer, CCRI, St Anna Kinderspital, Kinderspitalg.6, A-1090 Vienna, Austria; e-mail:renate.panzer@ccri.univie.ac.at.

Sign in via your Institution